Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial

Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha, Benjamin Young

APEX Research/Family Medicine, Denver, USA.
APEX Research/Family Medicine, Denver, USA;International Association of Providers of AIDS Care, Washington, USA.
Colorado School of Mines, Golden, USA;APEX Research/Family Medicine, Denver, USA.
GlaxoSmithKline, Research Triangle Park, USA.

DOI: 10.4236/wja.2014.41005                

Abstract

Decreased bone mineral density (BMD) and osteoporotic fractures are areas of increasing concern among HIV-infected persons. Particular concern is the rapid decline in BMD after initiation of antiretroviral treatment (ART). This report describes DEXA-assessed changes in BMD and body fat in a study of fifteen antiretroviral-na?ve adults initiating abacavir/lamivudine and raltegravir for 96 weeks. Median percent changes from baseline at weeks 48 and 96 in BMD were 0.29% and -0.11% (spine); -1.25% and -1.75% (left hip). Median percent changes from baseline in fat from baseline were -0.82% and -3.04% (trunk); 2.12% and 2.01% (limb). In this pilot study, ABC/3TC + RAL treatment had limited impact on BMD and body fat.

Keywords

Bonedensity; Abacavir; HIV; Integrase; Lamivudine; Raltegravir

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Brown, T.T. and Qaqish, R.B. (2006) Antiretroviral Therapy and the Prevalence of Osteopenia and Osteoporosis: A Meta-Analytic Review. AIDS, 20, 2165-2174. http://dx.doi.org/10.1097/QAD.0b013e32801022eb
[2]	Triant, V.A., Brown, T.T., Lee, H. and Grinspoon, S.K. (2008) Fracture Prevalence among Human Immunodeficiency Virus (HIV)-Infected versus Non-HIV-Infected Patients in a Large U.S. Healthcare System. The Journal of Clinical Endocrinology and Metabolism, 93, 3499-3504. http://dx.doi.org/10.1210/jc.2008-0828
[3]	Young, B., Dao, C., Buchacz, K., Baker, R. and Brooks, J.T. (2011) Higher and Increasing Rates of Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared to the General U.S. Population, 1994-2008. Clinical Infectious Diseases, 52, 1061-1068. http://dx.doi.org/10.1093/cid/ciq242
[4]	McComsey, G.A., Kitch, D., Daar, E.S., et al. (2011) Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovirdisoproxilfumarate-Emtricitabine along with Efavirenz or Atazanavir-Ritonavir: Aids Clinical Trials Group A5224s: A Substudy of ACTG A5202. The Journal of Infectious Diseases, 203, 1791-1801. http://dx.doi.org/10.1093/infdis/jir188
[5]	Yin, M.T., Zhang, C.A., McMahon, D.J., et al. (2012) Higher Rates of Bone Loss in Postmenopausal HIV-Infected Women: A Longitudinal Study. The Journal of Clinical Endocrinology and Metabolism, 97, 554-562. http://dx.doi.org/10.1210/jc.2011-2197
[6]	Yin, M.T., Kendall, M.A., Wu, X., et al. (2012) Fractures after Antiretroviral Initiation. AIDS, 26, 2175-2184. http://dx.doi.org/10.1097/QAD.0b013e328359a8ca
[7]	Bedimo, R., Maalouf, N.M., Zhang, S., Drechsler, H. and Tebas, P. (2012) Osteoporotic Fracture Risk Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents. AIDS, 26, 825-831. http://dx.doi.org/10.1097/QAD.0b013e32835192ae
[8]	Brown, T.T., McComsey, G.A., King, M.S., Qaqish, R.B., Bernstein, B.M. and da Silva, B.A. (2009) Loss of Bone Mineral Density after Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen. Journal of Acquired Immune Deficiency Syndromes, 51, 554-561. http://dx.doi.org/10.1097/QAI.0b013e3181adce44
[9]	Young, B., Vanig, T., DeJesus, E., et al. (2010) A Pilot study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-naïve HIV-1-Infected Patients: 48-Week Results of the SHIELD Trial. HIV Clinical Trials, 11, 260-269. http://dx.doi.org/10.1310/hct1105-260
[10]	Young, B., Vanig, T., DeJesus, E., Hawkins, T., St. Clair, M., Stancil, B., Ha, B. and the SHIELD Study Team (2011) 96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Patients: The SHIELD Trial. HIV Clinical Trials, 12, 228-233. http://dx.doi.org/10.1310/HCT1204-228
[11]	Young, B., Fransen, S., Greenberg, K.S., et al. (2011) Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy. Antiviral Therapy, 16, 253-256. http://dx.doi.org/10.3851/IMP1748
[12]	Haskelberg, H., Hoy, J.F., Amin, J., et al. (2012) Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS One, 7, e38377. http://dx.doi.org/10.1371/journal.pone.0038377
[13]	Rasmussen, T.A., Jensen, D., Tolstrup, M., et al. (2012) Comparison of Bone and Renal Effects in HIV-Infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial. PLoS One, 7, e32445. http://dx.doi.org/10.1371/journal.pone.0032445
[14]	Stellbrink, H.J., Orkin, C., Arribas, J.R., et al. (2010) Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study. Clinical Infectious Diseases, 51, 963-972. http://dx.doi.org/10.1086/656417
[15]	Reynes, J., Trinh, R., Pulido, F., et al. (2013) Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the Progress Study. AIDS Research and Human Retroviruses, 29, 256-265.
[16]	Ofotokun, I., Sheth, A.N., Sanford, S.E., et al. (2012) A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. AIDS Research and Human Retroviruses, 28, 1196-1206. http://dx.doi.org/10.1089/aid.2011.0336